Objective To investigate the clinical efficacy and safety of intraductal meibomian gland probing in the treatment of patients with meibomian gland dysfunction (MGD). Methods In a prospective randomized block design, 111 consecutive patients (111 eyes ) with MGD were divided into 3 groups. All subjects were age- and sex-matched among the 3 groups. The eye selected for the study in each subject was chosen on the basis of the most obvious symptoms. There were 37 eyes in each group. The conventional treatment group was treated only with antibiotic eye drops combined with topical steroids+artificial tears+local physical therapy; MGD patients in the intraductal probing group underwent intraductal probing with steel probes (Rhein Medical, Inc. USA) and 6~9 meibomian glands were probed in each eye; and the third group underwent intraductal probing combined with a drug(0.5% tobramycin dexamethasone eye drops) injected into the intraductal meibomian gland during the probing procedure. All subjects underwent sequential examinations before and after treatment as follows: evaluation of ocular surface disease symptoms using the ocular surface disease index (OSDI); tear film break-up time (BUT); corneal fluorescein staining (CFS); Schirmer I test (SIT), and lid margin and ocular surface examination by slit lamp. The parameters among the 3 groups were investigated and compared before treatment and 1 month after treatment. Confocal microscope was performed to detect the safety of the intraductal meibomian gland probing by observing both the morphology and density of meibomian gland (MG) acinar units. The data among the three groups were randomly compared by a two-way ANOVA and q test (Newman-Keuls); a paired t test was used to analyze the parameters in each group before treatment and 1 month after treatment. Results ①Before treatment, there were no statistical differences among the three groups in OSDI, BUT, CFS, SIT, or lid margin scores (P>0.05). ②There were statistical differences among the three groups 1 month after treatment(F=4.68, 4.17, 3.98, 3.67, 4.12, P<0.05). The changes in every parameter in the conventional treatment group were significantly lower than for those in the intraductal probing group (P<0.05) and in the intraductal probing group that received drug injections (P<0.05). Improvement was better in the intraductal probing group that received injections compared to the intraductal probing group but no statistically significant differences were seen in the parameters. ? ③1 month after treatment: except for the conventional treatment group, significant differences were noted in the data of OSDI, BUT, CFS, Schirmer I test, and lid margin scores in the intraductal probing group (t=2.543, 2.343, 2.456, 2.132, 2.237, respectively, P<0.05) and in the intraductal probing with drug injection group (t=2.713, 2.443, 2.496, 2.143, 2.249, respectively, P<0.05). ④The MG acinar cells can be clearly observed with confocal microscope. MG acinar cells showed that different forms were due to the location in different optical sections. The outer sections of MG acinar cells were tire-like, accompanied by bright reflective and gray cell cavities with highly reflective dot secretion. MGs were distributed in group-like aggregations and arranged irregularly. There were no degenerative changes in the morphology of MG acinar units as well as MG scars 1 month after probing. Conclusion Intraductal meibomian gland probing seems to provide rapid and lasting symptom relief and significant improvement in symptoms and signs of MGD in patients. Intraductal meibomian gland probing is a safe, effective technique for MGD.
覃冬菊,刘辉,徐建江. 腺管探通术治疗睑板腺功能障碍的临床观察[J]. 中华眼视光学与视觉科学杂志, 2014, 16(10): 615-621.
Qin Dongju,Liu Hui,Xu Jianjiang. Clinical research on intraductal meibomian gland probing in the treatment of patients with meibomian gland dysfunction. Chinese Journal of Optometry Ophthalmology and Visual science, 2014, 16(10): 615-621. DOI: 10.3760/cma.j.issn.1674-845X.2014.10.009
Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction:executive summary [J]. Invest Ophthalmol Vis Sci,2011,52:1922-1929.
[2]
董雪青,高莹莹. 睑板腺功能障碍的治疗进展[J]. 国际眼科纵览,2012,36:251-255.
[3]
Ole?觡ik A, Jiménez-Alfaro I, Alejandre-Alba N, et al. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplemetation in meibomian gland dysfunction[J]. Clin Interv Aging,2013,8:1133-1138.
[4]
Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction[J]. Cornea,2010,29:1145-1152.
[5]
Wladis EJ. Intraductal meibomian gland probing in the management of ocular rosacea[J]. Ophthalmic Plastic Reconstr Surg,2012,28:416-418.
[6]
Arita R, Itoh K, Maeda S, et al. Proposed diagnostic criteria for obstructive meibomian gland dysfunction[J]. Ophthalmology, 2009,116:2058-2063.
[7]
Ozcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome[J]. Ocul Immunol Inflamm,2007,15:389-393.
[8]
Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index[J]. Arch Ophthalmol,2010,128:94-101.
Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye[J]. Ocul Surf,2004,2:149-165.
[12]
Romero JM, Biser SA, Perry HD, et al. Conservative treatment of meibomian gland dysfunction[J]. Eye Cantact Lens,2004, 30:14-19.
[13]
Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction[J]. Cornea,2006,25:171-175.
[14]
Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients[J]. Exp Eye Res,2003,76:417-420.
[15]
Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnoses, classification, and grading[J]. Ocul Surf,2003,1:107-126.
[16]
McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer[J]. Ocul Surf,2003,1:97-106.
[17]
Obata H. Anatomy and histopathology of human meibomian gland[J]. Cornea,2002,21:S70-S74.
[18]
Wei A, Hong J, Sun X, et al. Evaluation of age-related changes in human palpebral conjunctiva and meibomian glands by in vivo confocal microscopy[J]. Cornea,2011,30:1007-1012.
Kobayashi A, Yoshita T, Sugiyama K. In vivo findings of the bulbar/palpebral conjunctiva and presumed meibomian glangds by laser scanning confocal microscopy[J]. Cornea,2005,24:985-988.
[21]
Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction[J]. Invest Ophthalmol Vis Sci,2011,52:2050-2064.